138 related articles for article (PubMed ID: 10188142)
1. Characterization of [3H]substance P binding sites in human skin.
Bianchi B; Matucci R; Danesi A; Rossi R; Ipponi P; Giannotti B; Johansson O; Cappugi P
J Eur Acad Dermatol Venereol; 1999 Jan; 12(1):6-10. PubMed ID: 10188142
[TBL] [Abstract][Full Text] [Related]
2. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
Ciucci A; Palma C; Manzini S; Werge TM
Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
[TBL] [Abstract][Full Text] [Related]
3. Radioiodinated substance P, neurokinin A, and eledoisin bind predominantly in NK1 receptors in guinea pig lung.
Geraghty DP; Mussap CJ; Burcher E
Mol Pharmacol; 1992 Jan; 41(1):147-53. PubMed ID: 1370705
[TBL] [Abstract][Full Text] [Related]
4. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
[TBL] [Abstract][Full Text] [Related]
5. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
6. Binding of the novel ligand [4,5-3H-Leu10]substance P to high-affinity NK-1 receptors on guinea pig lung membranes: modulation by GTP analogs and sulfhydryl modifying agents.
Aharony D; Catanese CA; Woodhouse DP
J Pharmacol Exp Ther; 1991 Oct; 259(1):146-55. PubMed ID: 1717678
[TBL] [Abstract][Full Text] [Related]
7. Characterization of guinea pig pulmonary neurokinin type 1 receptors using a novel antagonist ligand, [3H]FK888.
Miyayasu K; Mak JC; Nishikawa M; Barnes PJ
Mol Pharmacol; 1993 Sep; 44(3):539-44. PubMed ID: 7690449
[TBL] [Abstract][Full Text] [Related]
8. Presence of NK1 receptors on a mucosal-like mast cell line, RBL-2H3 cells.
Cooke HJ; Fox P; Alferes L; Fox CC; Wolfe SA
Can J Physiol Pharmacol; 1998 Feb; 76(2):188-93. PubMed ID: 9635159
[TBL] [Abstract][Full Text] [Related]
9. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
11. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
12. Septide: an agonist for the NK1 receptor acting at a site distinct from substance P.
Pradier L; Ménager J; Le Guern J; Bock MD; Heuillet E; Fardin V; Garret C; Doble A; Mayaux JF
Mol Pharmacol; 1994 Feb; 45(2):287-93. PubMed ID: 7509440
[TBL] [Abstract][Full Text] [Related]
13. High affinity binding sites for [3H]substance P in urinary bladders of cats with interstitial cystitis.
Buffington CA; Wolfe SA
J Urol; 1998 Aug; 160(2):605-11. PubMed ID: 9679937
[TBL] [Abstract][Full Text] [Related]
14. Canine intrinsic cardiac neurons involved in cardiac regulation possess NK1, NK2, and NK3 receptors.
Thompson GW; Hoover DB; Ardell JL; Armour JA
Am J Physiol; 1998 Nov; 275(5):R1683-9. PubMed ID: 9791091
[TBL] [Abstract][Full Text] [Related]
15. Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP kinase.
Jeurissen F; Kavelaars A; Korstjens M; Broeke D; Franklin RA; Gelfand EW; Heijnen CJ
J Immunol; 1994 Mar; 152(6):2987-94. PubMed ID: 7511635
[TBL] [Abstract][Full Text] [Related]
16. Effect of neurokinins on canine prostate cell physiology.
Walden PD; Marinese D; Srinivasan D; Tzoumaka E; Syyong HT; Ford AP; Bhattacharya A
Prostate; 2005 Jun; 63(4):358-68. PubMed ID: 15611996
[TBL] [Abstract][Full Text] [Related]
17. The NK1 receptor and its participation in the synergistic enhancement of corneal epithelial migration by substance P and insulin-like growth factor-1.
Nakamura M; Ofuji K; Chikama T; Nishida T
Br J Pharmacol; 1997 Feb; 120(4):547-52. PubMed ID: 9051288
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M
Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
[TBL] [Abstract][Full Text] [Related]
19. [3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.
Griffante C; Carletti R; Andreetta F; Corsi M
Br J Pharmacol; 2006 May; 148(1):39-45. PubMed ID: 16501582
[TBL] [Abstract][Full Text] [Related]
20. Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M; Boczek-Leszczyk E
J Physiol Pharmacol; 2008 Sep; 59(3):553-62. PubMed ID: 18953097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
